Similar to TDZ, DRD2 antagonists fluphenazine dihydrochloride35 and domperidone36 independently suppressed leukemic progenitor activity, providing convergent evidence that DRD2 is a biologically meaningful target in AML (Figure S3E). The gene discussed is DRD2; the disease is acute myeloid leukemia.